Spirea startup, supported by the Accelerate Cambridge programme run by Cambridge Judge’s Entrepeneurship Centre, has raised crucial funding and is aiming to target a potential $7.5 billion market for the treatment of multiple cancers. CEO Myriam Ouberai said: “Incorporation of our technology into ADC products will accelerate and energise the important transition away from the ‘one size fits all’ approach currently being pursued in ADC development, resulting in novel products with a competitive and differentiated profile. The platform has the power to unlock the development of a new generation of powerful and well-tolerated drugs, which have been so far inaccessible to many cancer patients.”
Read the full article [businessweekly.co.uk]
Brain food 
Compass 
Entrepreneurship 
In the media 
Network 
News 
Reasons why 
The lowdown 
Thinkers
Comments